Topline data were announced from a phase 3 trial evaluating evolocumab in adults at high cardiovascular risk without prior heart attack or stroke.
Amgen announced the launch of its direct-to-patient program providing eligible patients discounted pricing for evolocumab, a ...
Evolocumab, a PCSK9 inhibitor, reduced risk for major adverse CV events in people with no history of heart attack or stroke ...
The number of primary care providers in Oregon is flatlining — especially in rural areas. But experts say the problem is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback